SG174893A1 - Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline - Google Patents

Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline Download PDF

Info

Publication number
SG174893A1
SG174893A1 SG2011068426A SG2011068426A SG174893A1 SG 174893 A1 SG174893 A1 SG 174893A1 SG 2011068426 A SG2011068426 A SG 2011068426A SG 2011068426 A SG2011068426 A SG 2011068426A SG 174893 A1 SG174893 A1 SG 174893A1
Authority
SG
Singapore
Prior art keywords
methylcarbamoylmethyl
anilino
quinazoline
piperidin
oxy
Prior art date
Application number
SG2011068426A
Other languages
English (en)
Inventor
Kay Alison Boardman
Oliver Robert Cunningham
William Goundry
David Dermot Patrick Laffan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG174893A1 publication Critical patent/SG174893A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG2011068426A 2009-04-23 2010-04-22 Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline SG174893A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23
PCT/GB2010/050653 WO2010122340A2 (en) 2009-04-23 2010-04-22 Process 738

Publications (1)

Publication Number Publication Date
SG174893A1 true SG174893A1 (en) 2011-11-28

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011068426A SG174893A1 (en) 2009-04-23 2010-04-22 Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline

Country Status (14)

Country Link
US (1) US8450482B2 (enExample)
EP (1) EP2421827A2 (enExample)
JP (1) JP2012524769A (enExample)
KR (1) KR20120007059A (enExample)
CN (1) CN102459174A (enExample)
AR (1) AR076407A1 (enExample)
AU (1) AU2010240717A1 (enExample)
BR (1) BRPI1013854A2 (enExample)
CA (1) CA2758610A1 (enExample)
IL (1) IL215388A0 (enExample)
MX (1) MX2011011177A (enExample)
SG (1) SG174893A1 (enExample)
TW (1) TW201041871A (enExample)
WO (1) WO2010122340A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
US20070299092A1 (en) * 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente

Also Published As

Publication number Publication date
WO2010122340A8 (en) 2011-12-15
EP2421827A2 (en) 2012-02-29
AU2010240717A1 (en) 2011-10-27
JP2012524769A (ja) 2012-10-18
AR076407A1 (es) 2011-06-08
MX2011011177A (es) 2011-11-18
TW201041871A (en) 2010-12-01
IL215388A0 (en) 2011-12-29
WO2010122340A3 (en) 2011-09-09
KR20120007059A (ko) 2012-01-19
CN102459174A (zh) 2012-05-16
US20120108814A1 (en) 2012-05-03
US8450482B2 (en) 2013-05-28
BRPI1013854A2 (pt) 2017-05-16
CA2758610A1 (en) 2010-10-28
WO2010122340A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
PT2473049T (pt) Inibidores de tirosina quinase de bruton
EP2346837B8 (en) Methods of preparing quinazolinone derivatives
ZA201301679B (en) Inhibitors of bruton's tyrosine kinase
ZA201202552B (en) Inhibitors of bruton's tyrosine kinase
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
EP2167092A4 (en) QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3 KINASE
SI1981863T1 (sl) Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
ZA200903533B (en) Process for the preparation of rosuvastatin
PL2334622T3 (pl) Sposób wytwarzania trifluorowanych i tetrafluorowanych związków
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
PH12010502934A1 (en) Quinazoline derivatives
EP2382210A4 (en) INHIBITORS OF PYRIMIDINEDIAMINE KINASE
EP2291366A4 (en) PREPARATION OF IMATINIB MESYLATE
PL2387566T3 (pl) Sposób przygotowania rosuwastatyny
ZA201008283B (en) Fumarate salt of 4-(3-chloro-2-fluoroanilino) -7-methoxy-6-{[1-(n-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline
EP2069307A4 (en) PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
SG174893A1 (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin-4-yl] oxy} quinazoline
ZA201006135B (en) Process for the manufacture of [phenylsufanylphenyl]piperidines
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
HK1164285A (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin- 4-yl]oxy}quinazoline
IL215550A (en) Process for the preparation of a biphenyl ester 2-carboxylic acid moiety 1– [2–2] -chloro-4-formyl-5-methoxyphenyl) -carbamoylethyl] piperidene-4 ester yl and intermediate
EP2344472A4 (en) ISOCHINOLINONDERIVATE
TH0901002062A (th) 4-(3-คลอโร-2-ฟลูออโรแอนิลิโน)-7-เมธอกซิ-6-{[1-(n-เมธิลคาร์บามออิลเมธิล)พิเพอริดิน-4-อิล]ออกซิ}ควินาโซลีน ไดฟูมาเรท
GB0812609D0 (en) Process for the preparation of deoxynojirimycin
HK1158642A (en) Isoquinolinone derivatives